Dopamine D3 receptor antagonism - Still a therapeutic option for the treatment of schizophrenia

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 386, Issue 2, 2013, Pages 155-166

  Gross, Gerhard ^a   Wicke, Karsten ^a   Drescher, Karla U ^a  

^a ABBOTT GMBH AND CO KG   (Germany)

Author keywords

ABT 925; Atypical antipsychotics; Cognitive deficit in schizophrenia; D3 receptor PET; Dopamine D3 receptor; Negative symptoms of schizophrenia; PHNO imaging

Indexed keywords

ABT 127; ABT 925; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; GLUTAMATE RECEPTOR; GSK 598809; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDRO 2 ISOQUINOLINYL)ETHYL]CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE; N [4 [2 (8 CYANO 1,3A,4,9B TETRAHYDRO 1 BENZOPYRANO[3,4 C]PYRROL 2(3H) YL)ETHYL]PHENYL]ACETAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; S 33084; SK 277011; UNCLASSIFIED DRUG;

ANHEDONIA; BRAIN CORTEX; COGNITION; COGNITIVE DEFECT; DRUG POTENCY; ELECTRIC ACTIVITY; EXECUTIVE FUNCTION; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPOTHESIS; LIMBIC SYSTEM; MENTAL DISEASE; MESENCEPHALON; METABOLIC DISORDER; NEGATIVE SYNDROME; NERVE CELL; NONHUMAN; POSITIVE SYNDROME; REVIEW; SCHIZOPHRENIA; SOCIAL BEHAVIOR; TREATMENT OUTCOME; VENTRAL TEGMENTUM;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; COGNITION; DOPAMINE ANTAGONISTS; HUMANS; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA;

EID: 84873714086     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-012-0806-3     Document Type: Review

References (129)

1. Aghajanian GK, Bunney BS (1977) Dopamine "autoreceptors": pharmacological characterization by microiontophoretic single cell recording studies. Naunyn Schmiedebergs Arch Pharmacol 297:1-7
2. 3 receptor antagonist SB-277011-A alters activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study. J Pharmacol Exp Ther 294:1166-1174
3. Benes FM (2012) Nicotinic receptors and functional regulation of GABA cell microcircuitry in bipolar disorder and schizophrenia. In: Geyer M, Gross G (eds) Novel antischizophrenia treatments; Handb Exp Pharmacol 213:401-417. Springer, Heidelberg. doi: 10.1007/978-3-642-25758-2-13
4. Bespalov A, Jongen-Rêlo AL, van Gaalen M, Harich S, Schoemaker H, Gross G (2007) Habituation deficits induced by metabotropic glutamate receptors 2/3 receptor blockade in mice: reversal by antipsychotic drugs. J Pharmacol Exp Ther 320:944-950
5. 3 receptor antagonist in schizophrenic subjects. Clin Pharmacol Ther 89(Suppl 1):S76
6. Booij J, van Amelsvoort T (2012) Imaging as tool to investigate psychoses and antipsychotics. In: Gross G, Geyer M (eds) Current antipsychotics; Handb Exp Pharmacol 212. Springer, Heidelberg
7. 3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci USA 94:3363-3367
8. Bordet R, Ridray S, Schwartz JC, Sokoloff P (2000) Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats. Eur J Neurosci 12:2117-2123
9. Carlsson A (2002) Birth of dopamine: a Cinderella saga. Handb Exp Pharmacol 154/I:23-42
10. Carter CS, Barch DM (2007) Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative. Schizophr Bull 33:1131-1137
11. Castagné V, Moser PC, Porsolt RD (2009) Preclinical behavioral models for predicting antipsychotic activity. Adv Pharmacol 57:381-418
12. Chiodo LA, Bunney BS (1985) Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J Neurosci 5:2539-2544
13. Collip D, Myin-Germeys I, van Os J (2008) Does the concept of "sensitization" provide a plausible mechanism for the putative link between the environment and schizophrenia? Schizophr Bull 34:220-225
14. Coyle JT, Basu A, Benneyworth M, Balu D, Konopaske G (2012) Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. In: Geyer M, Gross G (eds) Novel antischizophrenia treatments; Handb Exp Pharmacol 213:267-295. Springer, Heidelberg. doi: 10.1007/978-3-642-25758-2-10
15. 2 receptors in reversal learning. Neuroscience 162:118-127
16. 3 receptors expressed by all mesencephalic dopamine neurons. J Neurosci 20:8677-8684
17. 3 receptor antagonist A-437203. Abstr Soc Neurosci 894.6
18. 3 receptor antagonist: neurochemical and electrophysiological studies in vivo. Abstr Soc Neurosci 913.19
19. Featherstone RE, Kapur S, Fletcher PJ (2007) The amphetamine-induced sensitized state as a model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 31:1556-1571
20. Fleischhacker W (2000) Negative symptoms in patients with schizophrenia with special reference to the primary versus secondary distinction. Encéphale 26(1):12-14
21. Fujisawa S, Buzsáki G (2011) A 4 Hz oscillation adaptively synchronizes prefrontal, VTA, and hippocampal activities. Neuron 72:153-165
22. Gainetdinov RR, Sotnikova TD, Grekhova TV, Rayevsky KS (1996) In vivo evidence for preferential role of dopamine D3 receptor in the presynaptic regulation of dopamine release but not synthesis. Eur J Pharmacol 308:261-269
23. 2 receptors in the rhesus monkey brain in vivo. Synapse 66:489-500
24. 2 receptors for antipsychotic activity. In: Gross G, Geyer M (eds) Current antipsychotics; Handb Exp Pharmacol 212. Springer, Heidelberg
25. 11C]-(+)-PHNO. Neuropsychopharmacology 36:887-895
26. 3 receptors have spatial working memory deficits. J Neurosci 22:5619-5629
27. 3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention. Cereb Cortex 15:1016-1024
28. 3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J Pharmacol Exp Ther 275:899-913
29. 3 (auto) receptors inhibit dopamine release in the frontal cortex of freely moving rats in vivo. J Neurochem 66:2209-2212
30. Grace AA, Bunney BS, Moore H, Todd CL (1997) Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci 20:31-37
31. 11C]raclopride in healthy humans. Hum Brain Mapp 29:400-410
32. 11C]-(+)-PHNO. Arch Gen Psychiatry 66:606-615
33. 3 receptor antagonist ABT-925. Int J Neuropsychopharmacol 13:273-287
34. Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R, Langen B, Logue S, Brennan J, Jiang L, Charych E, Egerland U, Liu F, Marquis KL, Malamas M, Hage T, Comery TA, Brandon NJ (2009) Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther 331:574-590
35. 3 receptor ligand, (+)-UH232, is a partial agonist. Eur J Pharmacol 282(1-3):R3-R4
36. 3 receptors in antipsychotic activity and cognitive functions. In: Geyer M, Gross G (eds) Novel antischizophrenia treatments; Handb Exp Pharmacol 213:167-210. Springer, Heidelberg. doi: 10.1007/978-3-642-25758-2-7
37. 3 receptor antagonists. Eur Neuropsychopharmacol 7(Suppl 2):S120
38. 3 receptor antagonists. Naunyn Schmiedebergs Arch Pharmacol 358:R375
39. 3 receptor antagonist: behavioral pharmacology studies. Abstr Soc Neurosci 913.20
40. 2 receptor expressing neurons. Neuropsychopharmacology 20:60-80
41. 3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats. Eur J Pharmacol 572:171-174
42. 2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15. Naunyn Schmiedebergs Arch Pharmacol 378:529-539
43. 3H] PD 128907. Psychopharmacology (Berl) 128:240-247
44. 3 receptors as a target for drug addiction pharmacotherapy: a review of preclinical evidence. CNS Neurol Disord Drug Targets 7:410-421
45. 3 receptor antagonists and antipsychotic drugs on the disruption of huddling behavior by dopamine agonists. Society for Neuroscience Abstract No.350.1
46. 3 receptors. Neuroscience 112:39-49
47. 3 receptor antagonists as therapeutic agents. Drug Discov Today 10:917-925
48. 3 agonists disrupt social behavior in rats. Brain Res 721:229-232
49. Kantrowitz JT, Javitt DC (2010) Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. Clin Schizophr Relat Psychoses 4:189-200
50. 2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 158:360-369
51. Kasper S, Barnas C, Heiden A, Volz HP, Laakmann G, Zeit H, Pfolz H (1997) Pramipexole as adjunct to haloperidol in schizophrenia. Safety and efficacy. Eur Neuropsychopharmacol 7:65-70
52. 3 receptor mutant mice. J Neurosci 18:2231-2238
53. 3 receptor binding affinities. Eur J Pharmacol 277:209-214
54. Kuepper R, Skinbjerg M, Abi-Dargham A (2012) The dopamine dysfunction in schizophrenia revisited: new insights into topography and course. In: Gross G, Geyer M (eds) Current antipsychotics; Handb Exp Pharmacol 212. Springer, Heidelberg
55. 3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex. Neuropsychopharmacology 28:839-849
56. 3 receptor antagonists enhance cortical acetylcholine levels measured with high-performance liquid chromatography/tandem mass spectrometry without anti-cholinesterases. J Neurosci Methods 157:25-31
57. 3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia. J Neural Transm 105:719-734
58. Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson A, Tamminga CA (1998b) Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl) -N-n-propylpiperidine (preclamol) in schizophrenia. Biol Psychiatry 43:2-11
59. 3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology (Berl) 179:567-575
60. 3 receptor and drug dependence: effects on reward or beyond? Neuropharmacology 49:525-541
61. 3 receptor agonist in schizophrenia. Eur Neuropsychopharmacol 13(suppl 4):S167-S168
62. 3 autoreceptors inhibits firing of ventral tegmental dopaminergic neurones in vivo. Eur J Pharmacol 275:R7-R9
63. 3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade. Neuropharmacology 45:174-181
64. 3 receptor. Neurotox Res 6:63-71
65. Lisman J (2011) Excitation, inhibition, local oscillations, or large-scale loops: what causes the symptoms of schizophrenia? Curr Opin Neurobiol Nov 11 [Epub ahead of print]
66. 2 antagonists. Eur Neuropsychopharmacol 19:23-33
67. 3 receptor heteromers: pharmacological properties and therapeutic significance. Curr Opin Pharmacol 10:100-107
68. Matsumoto M, Weickert CS, Akil M, Lipska BK, Hyde TM, Herman MM, Kleinman JE, Weinberger DR (2003) Catechol O-methyltransferase mRNA expression in human and rat brain: evidence for a role in cortical neuronal function. Neuroscience 116:127-137
69. 2-selective ex vivo but not in vitro. Neuropsychopharmacology 35:1826-1835
70. McKinzie DL, Bymaster FP (2012) Muscarinic mechanisms in psychotic disorders. In: Geyer M, Gross G (eds) Novel antischizophrenia treatments; Handb Exp Pharmacol 213;233-65. Springer, Heidelberg. doi: 10.1007/978-3-642-25758-2-9
71. Meltzer HY (2012) Serotonergic mechanisms as targets for existing and novel antipsychotics. In: Gross G, Geyer M (eds) Current antipsychotics; Handb Exp Pharmacol 212. Springer, Heidelberg
72. Meyer-Lindenberg A, Weinberger DR (2006) Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci 7:818-827
73. 3 receptor "knock-out" mice in the step-through passive-avoidance test: assessing the role of the endocannabinoid/endovanilloid systems. Pharmacol Res 61:531-536
74. 3 receptor antagonists. J Med Chem 53:374-391
75. 2 antagonist, S33138. Therapie 63:187-229
76. 3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats. Eur J Pharmacol 321:R7-R9
77. 3-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 293:1063-1073
78. 3-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 293:1048-1062
79. 2 receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. J Neurochem 100:1047-1061
80. 2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects. J Pharmacol Exp Ther 324:1212-1226
81. 2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors. J Pharmacol Exp Ther 324:587-599
82. 2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo. J Pharmacol Exp Ther 324:600-611
83. 3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. Int J Neuropsychopharmacol 13:1035-1051
84. Millan MJ, Agid Y, Brune M, Bullmore ET, Carter CS, Clayton NS, Connor R, Davis S, Deakin B, Derubeis RJ, Dubois B, Geyer MA, Goodwin GM, Gorwood P, Jay TM, Joels M, Mansuy IM, Meyer-Lindenberg A, Murphy D, Rolls E, Saletu B, Spedding M, Sweeney J, Whittington M, Young LJ (2012) Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov 11:141-168
85. 2A receptor antagonist M100907 significantly alters the activity of midbrain dopamine neurons: an in vivo electrophysiological study. Synapse 40:102-112
86. 11C]-(+)-PHNO. Schizophr Res 131:63-68
87. Möller HJ (2003) Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs 17:793-823
88. 3 receptors and drug craving: a translational approach. Neuropsychopharmacology. doi: 10.1038/npp.2012.171
89. 3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J Med Chem 48:3663-3679
90. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK (2004) Identification of separable cognitive factors in schizophrenia. Schizophr Res 72:29-39
91. Olincy A, Freedman R (2012) Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptor. Handb Exp Pharmacol 213:211-32. Springer, Heidelberg. doi: 10.1007/978-3-642-25758-2-8
92. Peleg-Raibstein D, Feldon J, Meyer U (2012) Behavioral animal models of antipsychotic drug actions. In: Gross G, Geyer M (eds) Current antipsychotics; Handb Exp Pharmacol 212. Springer, Heidelberg
93. 3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol 312:35-44
94. Porsolt RD, Moser PC, Castagné V (2010) Behavioral indices in antipsychotic drug discovery. J Pharmacol Exp Ther 333:632-638
95. 3 receptors co-exist at the cell surface. J Biol Chem 287:8864-8878
96. 3 receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 294:1154-1165
97. 3 receptor antagonist ABT-925 in patients with acute schizophrenia. J Clin Psychopharmacol 31:221-225
98. 3 dopamine receptor-mediated inhibitory function. Neuropsychopharmacology 31:2368-2375
99. 3 dopamine receptor, behavioral sensitization, and psychosis. Neurosci Biobehav Rev 25:427-443
100. 2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology (Berl) 193:121-136
101. Scatton B, Claustre Y, Cudennec A, Oblin A, Perrault G, Sanger DJ, Schoemaker H (1997) Amisulpride: from animal pharmacology to therapeutic action. Int Clin Psychopharmacol 12(Suppl 2):S29-S36
102. Schmidt WJ, Beninger RJ (2006) Behavioural sensitization in addiction, schizophrenia, Parkinson's disease and dyskinesia. Neurotox Res 10:161-166
103. 3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280:83-97
104. 3 receptors in vivo. Eur J Pharmacol 218:373-375
105. 3 receptors in the rat brain: a quantitative autoradiographic study. Histochem J 28:791-799
106. 3 receptor antagonist A-437203 on the development and expression of locomotor sensitization to quinpirole in rats. Abstr Soc Neurosci 350.1
107. 11C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry 68:392-399
108. SIRS (2012) The 3rd Schizophrenia International Research Society Conference, 14-18 April 2012, Florence, Italy: Summaries of oral sessions. Schizophr Res 141(1):e1-e24
109. 2 receptor agonist 7-OH-DPAT induces cognitive impairment in the marmoset. Pharmacol Biochem Behav 63:201-211
110. 3 as a target for neuroleptics. Nature 347:146-151
111. 3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 5:25-43
112. 3 receptor with glutamate pathways: implications for the treatment of schizophrenia. Naunyn Schmiedebergs Arch Pharmacol: September 22 [Epub ahead of print]
113. 3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res 779:58-74
114. Svensson TH (2000) Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs. Brain Res Brain Res Rev 31:320-329
115. Tost H, Alam T, Meyer-Lindenberg A (2010) Dopamine and psychosis: theory, pathomechanisms and intermediate phenotypes. Neurosci Biobehav Rev 34:689-700
116. 3 signal and anatomy. Neuroimage 54:264-277
117. Ukai M, Tanaka T, Kameyama T (1997) Effects of the dopamine D3 receptor agonist, R(+)-7-hydroxy-N, N-di-n-propyl-2-aminotetralin, on memory processes in mice. Eur J Pharmacol 324:147-151
118. 3 receptor antagonist A-437203. Abstr Soc Neurosci 894.5
119. Ungless MA, Grace AA (2012) Are you or aren't you? Challenges associated with physiologically identifying dopamine neurons. Trends Neurosci 35(7):422-430
120. Vauquelin G, Bostoen S, Vanderheyden P, Seeman P (2012) Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism. Naunyn Schmiedebergs Arch Pharmacol 385:337-372
121. 2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berl) 150:422-429
122. 2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex. Neuropsychopharmacology 37:770-786
123. 2 receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment. Int J Neuropsychopharmacol 15:471-484
124. 3 receptors. Eur J Pharmacol 424:85-90
125. 3 receptor is critical for spatial learning and related signaling in the hippocampus. Neuroscience 169:1511-1519
126. 3 receptor. Eur J Pharmacol 627:167-172
127. Young JW, Zhou X, Geyer MA (2010) Animal models of schizophrenia. Curr Top Behav Neurosci 4:391-433
128. Young JW, Amitai N, Geyer MA (2012) Behavioral animal models of pro-cognitive treatments for schizophrenia. In: Geyer M, Gross G (eds) Novel antischizophrenia treatments; Handb Exp Pharmacol 213:39-79. Springer, Heidelberg. doi: 10.1007/978-3-642-25758-2-3
129. 3 receptor agonist effects of (+)-PD 128,907 on dialysate dopamine at low doses. Neuropharmacology 41:351-359